PharmExec Blog

H1N1 Vaccine Quantities to Fall Short of Predictions

Gripe A H1N1
Image by â– Guerry via Flickr

The US may not have as many H1N1 flu vaccines available from the get-go as originally anticipated, CBS News reported on Tuesday.

According to the report, approximately 45 million doses will be available in mid-October—that’s down from the original plan of 120 million doses. The new plan calls for an additional 20 million doses to be distributed each week after the first batch of vaccines are given.

GlaxoSmithKline announced last Friday that it had begun development for the new vaccine, and that it had locked up enrollment for the first clinical study.

“GSK is making good progress with the development of its pandemic vaccine.” Enrollment into the first study has been completed, and in total GSK will conduct 16 clinical trials of its pandemic vaccine in over 9,000 individuals across Europe, Canada, and the US,” stated Thomas Breuer, head of Global Clinical R&D and chief medical officer of GSK Biologicals. “We continue to work closely with regulators and governments to assess and develop this vaccine.”

Medimmune has also started clinical trials on its H1N1 vaccine, and told the Washington Business Journal that it expects to manufacturer far more vaccines than the 12.8 million doses the government asked it to produce.

Meanwhile, Novartis has already begun shipping its seasonal influenza vaccine to get that out of the way before the second wave of the H1N1 flu hits.

“With the (A) H1N1 influenza pandemic underway, it is important that we take every possible precaution to help protect US citizens from all circulating strains of influenza,” stated Andrin Oswald, CEO of Novartis Vaccines and Diagnostics, in a release. “By receiving the seasonal influenza vaccine early, physicians and public health officials can better prepare for the upcoming flu season.”

Reblog this post [with Zemanta]
This entry was posted in Manufacturing and tagged , , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

2 Comments

  1. Posted August 24, 2009 at 2:15 am | Permalink

    How effective are these vaccines? With the ever mutating H1N1 strains, can these vaccines be considered “Trial and Error” kind of a solution?

    We hope people can pay attention on their health more than just depending on the vaccines. In fact this is not only individual responsibility but rather a social responsibility.

    Definitely developing vaccines are critical as there are many people who are susceptible to H1N1 flu such as Immunocompromised, asthmatic, etc. Definitely priority should be given to them to receive the “effective” vaccines.

  2. Posted February 5, 2010 at 1:18 am | Permalink

    The best treatment for influenza infections in humans is prevention by vaccination. Work by several laboratories has recently produced vaccines. The first vaccine released in early October 2009 was a nasal spray vaccine. It is approved for use in healthy individuals ages 2 through 49. This vaccine consists of a live attenuated H1N1 virus and should not be used in anyone who is pregnant or immunocompromised. The injectable vaccine, made from killed H1N1, became available in the second week of October. This vaccine is approved for use in ages 6 months to the elderly, including pregnant females. Both of these vaccines have been approved by the CDC only after they had conducted clinical trials to prove that the vaccines were safe and effective. However, caregivers should be aware of the vaccine guidelines that come with the vaccines, as occasionally, the guidelines change. Please see the sections below titled “Can novel H1N1 swine flu be prevented with a vaccine?” and the timeline update for the current information on the vaccines.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta